March 1, 2016

Verseon Corporation (“Verseon” or the “Company”)

Additional Listing and Total Voting Rights

Verseon, a technology-based pharmaceutical company, announces that application has been made for 21,388 new Common Shares of par value $0.001 each (the "Common Shares") to be admitted to trading on AIM pursuant to issued restricted stock grants (the "Exercise").

The 21,388 new Common Shares issued pursuant to the Exercise will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on 3 March 2016 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,376,369 Common Shares.  The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 151,376,369. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information please contact:

Verseon Corporation +1 (510) 225 9000
Arthur Shmurun / Amy Thai  
   
Cenkos Securities (NOMAD and Broker) +44 (0) 20 7397 8900
Christopher Golden / Mark Connelly  
   
Abchurch Communications Ltd (PR Advisers) +44 (0) 20 7398 7719
Jamie Hooper / Alex Shaw  

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen